ClinicalTrials.gg
Drug

GLPG0634 clinical trials

Also written Filgotinib, GLPG0634 and GS-6034.

studies test it
50
open now
8
in phase 3
18
first study started
2010

How each study uses GLPG0634 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the GLPG0634 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
24 Sept 2020 · Jyseleca · EMEA/H/C/005113 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Jyseleca
7
GLPG0634 tablets
2
filgotinib 200mg/day
2

Development codes

GLPG0634
30
GS-6034
26

Other names

Filgotinib
37

Studies by the year they started

50 studies that test it; most in 2017 (13)

Studies that test GLPG0634, by start year
YearStudies
20101
20112
20122
20133
20144
20165
201713
20181
20193
20203
20212
20222
20232
20243
20252
20262

By phase

A phase 1/2 study counts in both.

Phase 1
10
Phase 2
18
Phase 3
18
Phase 4
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 44 · Other 6

Galapagos NV (19) · Gilead Sciences (16) · Alfasigma S.p.A. (7) · Lakefront Biotherapeutics NV (2) · Leiden University Medical Center (1) · University Hospital, Toulouse (1) · UMC Utrecht (1) · R.Bos (1)

Often tested with

Tested in the same studies.

Lanraplenib (3) · Methotrexate (1) · Tirabrutinib (1) · Baricitinib (1) · Tofacitinib (1) · Upadacitinib (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 2, 1 in phase 3

Studies that test GLPG0634, phase 3 first.

Studies

Open first, then newest update. How each study uses GLPG0634 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 50

See all 50 studies that test GLPG0634 →

Given beside what is tested · 1 — GLPG0634 is usual care or a partner of the new treatment

Codes

What other systems call GLPG0634 · ClinicalTrials.gg INT006381

  • MeSH (NLM) C584571GLPG0634One source ClinicalTrials.gov

Also registered as filgotinib (UNII 3XVL385Q0M) and filgotinib hydrochloride (UNII 2CQ8Y0B8XQ).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.